secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001437749-25-038157
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences awards CEO Barry $355K bonus tied to simufilam TSC epilepsy exploration
--------------------------------------------------------------------------------

- Board approved cash bonuses for 2025: CEO Richard Barry $355,000, CFO Eric Schoen $215,000.
- Performance measures include exploring simufilam for Tuberous Sclerosis Complex-related epilepsy.
- Other goals: building TSC expertise team and budgeting/expense management.
- Bonuses reflect contributions in advancing new potential indication for simufilam beyond Alzheimer's.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925038157/0001437749-25-038157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925038157/sava20251217_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer